title: Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme.
abstract: The aim of this study was to assess the activity and safety of bevacizumab (BEV) and fotemustine (FTM) for the treatment of recurrent glioblastoma multiforme (GBM) patients and explore the potential prognostic parameters on survival. This study retrospectively analyzed all patients with GBM who were treated with at least one cycle of BEV and FTM from July 2010 to October 2012. A total of 176 patients with recurrent GBM were enrolled. The response rate and disease control rate were 46.6% and 90.9%, respectively. A 6-month PFS rate of 33.3% (95% CI: 26.5%-40.3%) and a median PFS of 5.0 (95% CI: 2.4-7.5) months were observed. The median OS was 8.0 (95% CI: 6.7-9.2) months. Multivariate analysis showed that risk factors with a significant influence on the PFS of all patients were Karnofsky Performance Status (KPS) (≥70 versus <70, HR = 0.53, 95% CI: 0.39-0.73, and P = 0.01) and MGMT status (methylated versus unmethylated, HR = 0.69, 95% CI: 0.52-0.97, and P = 0.04). The most common treatment-related adverse events were fatigue, proteinuria, hypophonia, hypertension, thrombocytopenia, anemia, and neutropenia. In conclusion, combination of BEV with FTM is well tolerated and may derive some clinical benefits in recurrent GBM patients. Higher KPS and MGMT promoter hypermethylation were suggested to be associated with prolonged survival.
authors: Department of Neurology, Xuzhou Center Hospital, Xuzhou 221009, China.
authors: Zhiguang
authors: Z
authors: Liu
authors: Department of Neurology, Xuzhou Center Hospital, Xuzhou 221009, China.
authors: Guanqun
authors: G
authors: Zhang
authors: Department of Neurology, Xuzhou Center Hospital, Xuzhou 221009, China.
authors: Liang
authors: L
authors: Zhu
authors: Department of Neurology, Xuzhou Center Hospital, Xuzhou 221009, China.
authors: Jiangbo
authors: J
authors: Wang
authors: Department of Cancer, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
authors: Dongbo
authors: D
authors: Liu
authors: Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
authors: Lifei
authors: L
authors: Lian
authors: Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
authors: Jianlin
authors: J
authors: Liu
authors: Department of Neurology, Zhongshan Hospital, Xiamen University, Xiamen 361004, China.
authors: Tianbao
authors: T
authors: Lai
authors: Department of Neurology, Zhongshan Hospital, Xiamen University, Xiamen 361004, China.
authors: Xiaorong
authors: X
authors: Zhuang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D000068258:Bevacizumab; C054368:fotemustine